A 3-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of MK-0873 Following Cumulative Patch and Repeated Max Area Applications in Healthy Subjects and Psoriasis Patients
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2017
At a glance
- Drugs MK 0873 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 26 Jun 2012 Actual patient number 42 added as reported by ClinicalTrials.gov.
- 05 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.